文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

作者信息

Maulhardt Markus, Call Simon, Boyadzhiev Hristo, Albici Anca Maria, Hörster Keven, Boquoi Amelie, Janjetovic Snjezana, Ossami Saidy Anna, Teichert Marcel, Brioli Annamaria, Schultze-Florey Christian, Heidel Florian, Schindler Philipp, Schub Natalie, Aydilek Enver, Stelljes Matthias, Daskalakis Michael, Krekeler Carolin, Hasenkamp Justin, Khandanpour Cyrus, Bacher Ulrike, Reinhardt Hans Christian, Lenz Georg, Stölzel Friedrich, Pabst Thomas, von Tresckow Bastian, Wulf Gerald, Berning Philipp, Shumilov Evgenii

机构信息

Department of Hematology and Medical Oncology University Hospital Goettingen Goettingen Germany.

Department of Medicine A, Hematology, Oncology and Pneumology University Hospital Muenster Muenster Germany.

出版信息

Hemasphere. 2025 Aug 18;9(8):e70192. doi: 10.1002/hem3.70192. eCollection 2025 Aug.

DOI:10.1002/hem3.70192
PMID:40832014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12358732/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1281/12358732/7da5b84bd892/HEM3-9-e70192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1281/12358732/7da5b84bd892/HEM3-9-e70192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1281/12358732/7da5b84bd892/HEM3-9-e70192-g001.jpg

相似文献

[1]
Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Hemasphere. 2025-8-18

[2]
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.

Transplant Cell Ther. 2024-8

[3]
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.

Blood. 2025-7-10

[4]
Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

J Clin Pharmacol. 2025-7-10

[5]
Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.

Clin Drug Investig. 2022-12

[6]
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma.

Nat Commun. 2025-7-4

[7]
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis.

Hematol Oncol. 2025-7

[8]
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.

Future Oncol. 2022-1

[9]
FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma.

Clin Cancer Res. 2025-8-14

[10]
Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.

Transplant Cell Ther. 2024-6

本文引用的文献

[1]
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement.

Blood Adv. 2025-3-11

[2]
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement.

Hemasphere. 2023-11-30

[3]
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.

Blood. 2022-6-9

[4]
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.

Blood. 2022-4-14

[5]
Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission.

Front Oncol. 2021-11-17

[6]
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Lancet. 2021-7-24

[7]
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

N Engl J Med. 2021-2-25

[8]
Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma.

Hemasphere. 2020-7-15

[9]
Multiple myeloma with central nervous system relapse.

Haematologica. 2020-7

[10]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索